Glaukos (GKOS) Return on Capital Employed (2015 - 2026)
Glaukos' (GKOS) quarterly Return on Capital Employed came in at 24.72% in Q1 2026, down 1320.0% year-on-year from 2.03% in Q1 2025, and down 4.69% on a QoQ basis from 23.62% in Q4 2025.
Glaukos (GKOS) Return on Capital Employed (2015 - 2026) Analysis & Trends
Glaukos (GKOS) has 12 years of Return on Capital Employed data on file, last reported at 24.72% in Q1 2026.
- On a quarterly basis, Return on Capital Employed fell 1320.0% year-over-year to 24.72% in Q1 2026; TTM through Mar 2026 was 24.72%, a 1320.0% decrease from a year earlier, with the FY2025 full-year figure at 23.97%, down 1010.0% from the prior year.
- Return on Capital Employed for Q1 2026 stood at 24.72%, down from 23.62% in the prior quarter.
- Over the last five years, Return on Capital Employed for GKOS reached as high as 1.13% in Q1 2022 and fell as low as 24.72% in Q1 2026.
- Historically, Return on Capital Employed has averaged 12.77% across 5 years, with a median of 13.52% in 2023.
- Across the five-year window, Return on Capital Employed surged 1106 bps in 2022 and tumbled 1320 bps in 2026, its largest moves.
- Year by year, Return on Capital Employed stood at 8.82% in 2022, then tumbled by 68 bps to 14.78% in 2023, then climbed by 5 bps to 13.98% in 2024, then slumped by 69 bps to 23.62% in 2025, then slipped by 5 bps to 24.72% in 2026.
- Per Business Quant data, the three most recent Return on Capital Employed figures were 24.72% in Q1 2026, 23.62% in Q4 2025, and 9.76% in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn | 9.61% |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn | 12.24% |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn | 8.02% |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn | 9.62% |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn | 11.13% |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn | 24.24% |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn | 8.38% |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn | 9.30% |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - | - |
| 10 | Glaukos | 8.83 Bn | 8.73 Bn | 117.23 Mn | -24.72% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -24.72% |
| Dec 31, 2025 | -23.62% |
| Sep 30, 2025 | -9.76% |
| Jun 30, 2025 | -10.77% |
| Mar 31, 2025 | -11.53% |
| Dec 31, 2024 | -13.98% |
| Sep 30, 2024 | -15.54% |
| Jun 30, 2024 | -15.84% |
| Mar 31, 2024 | -15.59% |
| Dec 31, 2023 | -14.78% |
| Sep 30, 2023 | -13.98% |
| Jun 30, 2023 | -13.03% |
| Mar 31, 2023 | -13.52% |
| Dec 31, 2022 | -8.82% |
| Sep 30, 2022 | -6.93% |
| Jun 30, 2022 | -3.48% |
| Mar 31, 2022 | -1.13% |
| Dec 31, 2021 | -3.31% |
| Sep 30, 2021 | -2.66% |
| Jun 30, 2021 | -7.28% |